Kneu Health is a technology company.
Kneu Health has raised $6.0M across 1 funding round.
Kneu Health has raised $6.0M in total across 1 funding round.
Kneu Health is a University of Oxford spinout developing an AI-powered neurology care platform that transforms standard smartphones into tools for real-time remote monitoring of Parkinson's disease and dementia.[1][2][3] The platform combines digital biomarkers from voice, movement, and memory analysis with clinician dashboards and patient apps to enable proactive care, early detection, and reduced hospital admissions, serving patients, caregivers, and clinicians in the NHS, US health systems like Cedars-Sinai and Mass General Brigham, and beyond.[1][2][6] Backed by 10 years of research, over 700 hours of co-design, and a dataset of 500,000+ digital measures from 1,400+ participants, it has FDA clearance, UKCA marking, and demonstrated 30% efficiency gains in pilots while raising $5.6 million in seed funding (total $11.2 million).[1][2][4][6]
Kneu Health (formerly Neu Health) emerged as a spinout from the University of Oxford, building on a decade of research by neurologists, neuroscientists, and data scientists validated in trials with over 1,500 participants and published in peer-reviewed journals.[1][4][6] The idea stemmed from addressing neurology's shift needs: long wait times, fragmented reactive care, and lack of objective data between episodic clinic visits, particularly for fast-rising conditions like Parkinson's and dementia projected to affect 200 million by 2050.[1][4] Early traction came through NHS pilots showing reduced emergency admissions and care shifts to community settings, plus US validations, leading to 2024 HSJ Digitising Patient Care Award wins and partnerships with major charities.[1][2]
Kneu Health rides the neurodegeneration monitoring wave amid surging Parkinson's and dementia cases, fueled by aging populations and tech advances in AI/sensor analysis of symptoms like tremors and gait.[1][2][6] Timing aligns with NHS priorities for digitizing long-term conditions, relieving workforce pressures, and enabling community-based care, plus US demand for objective data beyond subjective scales.[1][6] Market forces favor it: regulatory nods (FDA-cleared), validated research, and investor interest in a flurry of symptom-tracking startups (e.g., Rune Labs, Empatica), positioning Kneu to influence ecosystem shifts toward continuous intelligence, pharma trials, and scalable prevention.[2][6] By bridging care gaps and supporting 1.4 million+ UK dementia cases alone, it accelerates digital health adoption in neurology.[1]
Kneu Health is poised to expand UK Parkinson's pathways across multi-site systems, scale dementia pilots into primary care partnerships, and deepen US contracts with systems like Cedars-Sinai (an investor).[1][2][6] Trends like AI biomarker precision, remote monitoring mandates, and neurodegeneration's global rise will propel growth, potentially reshaping care from reactive to predictive and influencing standards for 200 million future patients.[1][4] Its Oxford roots and track record suggest evolving influence as a leader in proactive neurology, easing system pressures while unlocking outcomes in an underserved field.[1][2]
Kneu Health has raised $6.0M in total across 1 funding round.
Kneu Health's investors include Pitango Venture Capital.
Kneu Health has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $6.0M Seed | Pitango Venture Capital |